Research shows glycyrrhizin reduces intestinal cell death in mice with inflammatory bowel disease — Evidence Review
Published in Stem Cell Reports, by researchers from University of Tokyo
Researched by
— the AI search engine for science
Table of Contents
Researchers at the University of Tokyo have developed a stem cell-based human intestinal model to screen treatments for inflammatory bowel disease (IBD), identifying glycyrrhizin—a compound from black licorice—as a promising candidate for reducing intestinal inflammation and cell death. Multiple related studies largely support the beneficial anti-inflammatory and gut-protective roles of glycyrrhizin and licorice derivatives, reinforcing these new findings.
- Previous animal and cell studies show glycyrrhizin and related licorice compounds reduce intestinal inflammation, protect gut barrier integrity, and modulate immune responses, aligning closely with the new study's results 2 4 5 8 14.
- Glycyrrhizin’s mechanisms appear to include inhibition of pro-inflammatory cytokines, restoration of epithelial barrier proteins, and modulation of gut microbiota, all of which are reported in related research and echo the protective effects observed in the stem cell model 1 2 4 8 9 14.
- While much of the supporting evidence comes from preclinical models, the consistency across studies suggests glycyrrhizin and licorice extracts may have broad therapeutic potential for intestinal inflammatory conditions, though clinical validation in humans remains necessary 2 4 11 14.
Study Overview and Key Findings
Inflammatory bowel disease is a chronic, relapsing disorder for which current treatments often fail to deliver lasting relief. Developing new therapies has been hindered by the lack of robust laboratory models that faithfully replicate the human intestinal environment. In this context, the recent study led by Yu Takahashi introduces a human stem cell-derived intestinal model that mimics IBD-like inflammation and damage, enabling high-throughput drug screening. The discovery of glycyrrhizin as a top candidate for reducing intestinal cell death is notable, especially given its longstanding presence in traditional medicine.
| Property | Value |
|---|---|
| Organization | University of Tokyo |
| Journal Name | Stem Cell Reports |
| Authors | Yu Takahashi |
| Population | Mice with IBD |
| Sample Size | 3,500 compounds screened |
| Methods | In Vitro Study |
| Outcome | Intestinal inflammation, cell death |
| Results | Glycyrrhizin significantly reduced intestinal cell death. |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant literature:
- glycyrrhizin inflammatory bowel disease effects
- intestinal cell death glycyrrhizin mechanism
- black licorice compounds gut health research
Below, related studies are grouped by key research questions and topics:
| Topic | Key Findings |
|---|---|
| How does glycyrrhizin impact intestinal inflammation and cell death in IBD models? | - Glycyrrhizin and its derivatives reduce inflammation and ameliorate colitis in animal models, lowering pro-inflammatory cytokines and improving intestinal health 2 4 5. - Glycyrrhizin suppresses cell death and restores barrier function in models of intestinal injury 8 9. |
| What mechanisms underlie glycyrrhizin’s protective effects on the gut? | - Glycyrrhizin modulates immune responses (reducing Th17 proliferation, inhibiting HMGB1, and shifting cytokine balance) 2 4 14. - Glycyrrhizin and licorice compounds restore epithelial barrier proteins and promote intestinal homeostasis via pathways such as HuR and PI3K/AKT 8 9 15. |
| Does glycyrrhizin or licorice alter the gut microbiota or related metabolic processes? | - Licorice extracts and glycyrrhizin modulate gut microbiota, increasing beneficial bacteria and short-chain fatty acids, which support barrier integrity 1 3 12 13 14. - Restoration of microbial balance may contribute to reduced inflammation and improved metabolic health 1 12 13 14. |
| What is the broader evidence for safety and efficacy of licorice compounds in inflammation? | - Systematic reviews and preclinical studies highlight anti-inflammatory activity of licorice components, though side effects and optimal dosing remain areas for further study 11. - Licorice and its compounds are traditionally used for digestive health, with modern studies supporting these uses 11 14. |
How does glycyrrhizin impact intestinal inflammation and cell death in IBD models?
Several related studies confirm that glycyrrhizin and its metabolites can alleviate intestinal inflammation and reduce cell death in preclinical models. These effects are observed in chemically induced colitis in mice, where glycyrrhizin reduces pro-inflammatory cytokines and ameliorates tissue injury. The new stem cell-based model adds further evidence by demonstrating direct protection against inflammation-induced cell death in human-derived intestinal tissue.
- Glycyrrhizin improves colitis symptoms, reduces inflammatory mediators, and protects against epithelial injury in mouse models 2 4 5.
- Its administration leads to decreased levels of cytokines such as IL-17, TNF-α, and IFN-γ in inflamed intestinal tissues 2 4.
- Glycyrrhizin reduces cell death and restores barrier function after injury 8 9.
- The new findings agree with these results, confirming glycyrrhizin’s protective effects in both animal and stem cell-derived human models 2 4 5 8 9.
What mechanisms underlie glycyrrhizin’s protective effects on the gut?
The literature indicates that glycyrrhizin’s anti-inflammatory and cytoprotective actions are mediated through multiple immune and cellular pathways. These include inhibition of HMGB1 (a key pro-inflammatory mediator), modulation of dendritic cell and macrophage activity, suppression of Th17 cell proliferation, and normalization of cytokine production. Recent studies also highlight the restoration of epithelial barrier proteins and maintenance of homeostatic signaling pathways (such as HuR and PI3K/AKT), which support tissue integrity and repair.
- Glycyrrhizin decreases HMGB1-induced activation of immune cells, reducing inflammation 2 4.
- It shifts cytokine balance towards an anti-inflammatory profile by increasing IL-10 and reducing pro-inflammatory cytokines 4 14.
- Restoration of epithelial barrier proteins and signaling (HuR, occludin, etc.) helps maintain intestinal homeostasis 8 9.
- These mechanisms are consistent with the new study’s findings of reduced cell death and inflammation in the intestinal model 2 4 8 9 14 15.
Does glycyrrhizin or licorice alter the gut microbiota or related metabolic processes?
Mounting evidence suggests glycyrrhizin and licorice extracts can beneficially modulate the gut microbiota. Studies demonstrate increases in beneficial bacteria (e.g., Lactobacillus, Akkermansia), reductions in pathogenic species, and enhanced production of short-chain fatty acids, all of which are linked to improved gut barrier function and reduced inflammation. These microbiota-driven effects may underlie some of the observed improvements in IBD and metabolic conditions.
- Licorice and glycyrrhizin increase beneficial bacteria, reduce harmful species, and enhance short-chain fatty acid production 1 3 12 13 14.
- Modulation of the microbiome is associated with improved metabolic profiles and lowered inflammatory markers 1 12 13 14.
- These changes contribute to restored intestinal barrier function and decreased disease severity 1 3 13 14.
- The new study did not directly assess microbiota, but its findings are consistent with the broader pattern of gut-protective effects 1 3 12 13 14.
What is the broader evidence for safety and efficacy of licorice compounds in inflammation?
Systematic reviews and preclinical research support licorice’s anti-inflammatory properties across a range of conditions, including IBD and other digestive disorders. However, questions remain regarding safety, optimal dosing, and potential side effects, particularly with long-term use or in vulnerable populations. These issues underscore the need for careful clinical evaluation even as preclinical evidence accumulates.
- Licorice extracts and isolated compounds have demonstrated anti-inflammatory efficacy in numerous models, with mechanisms involving TNF-α, MMPs, and free radical reduction 11.
- Traditional uses of licorice for digestive and inflammatory disorders are increasingly supported by modern pharmacological studies 11 14.
- Adverse effects, such as those related to cortisol-like activity, highlight the importance of further pharmacokinetic and safety studies 11.
- The new study’s focus on preclinical models is an important step, but clinical validation is needed 11 14.
Future Research Questions
Despite promising preclinical results, further research is needed to clarify glycyrrhizin’s safety, efficacy, and mechanisms in human IBD. Gaps include the absence of clinical trials, incomplete understanding of long-term effects, and the need to optimize delivery and dosing strategies.
| Research Question | Relevance |
|---|---|
| Does glycyrrhizin reduce intestinal inflammation and cell death in humans with IBD? | Clinical trials are necessary to determine if glycyrrhizin’s protective effects in animal and cell models translate to human patients with IBD, as most current evidence is preclinical 2 4 11. |
| What are the long-term safety and side effect profiles of glycyrrhizin in chronic use for IBD? | Licorice and glycyrrhizin may cause adverse effects with prolonged use, making it important to assess safety, especially in vulnerable populations 11. |
| How does glycyrrhizin modulate the gut microbiota in the context of IBD? | Understanding the microbiota-mediated mechanisms could inform combination therapies and identify patient subgroups most likely to benefit 1 3 14. |
| What are the optimal dosing and delivery strategies for glycyrrhizin in treating intestinal inflammation? | Determining effective and safe dosing regimens is critical for clinical translation, as highlighted in systematic reviews 11. |
| Can stem cell-derived intestinal models predict therapeutic responses in IBD patients? | Evaluating the predictive validity of these models could accelerate drug discovery and personalize IBD treatment 2 4. |